AMENDMENTS TO THE CLAIMS

1-13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition comprising (a) a therapeutically effective amount of an hydrophobic active principle and (b) a self micro-emulsifying carrier, said self micro-emulsifying carrier comprising:

(i) a lipophilic phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group consisting of C8-C18 fatty acids;

(ii) a surfactant phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C8) and capric acid (C10); and

(iii) a co-surfactant phase comprising ~~at least one ester of a polyvalent alcohol with at least one fatty acid chosen from a group consisting of~~ propylene glycol monocaprylate;

said surfactant and co-surfactant being in a ratio by weight between 0.2 and 6.

15. (Currently Amended) A ~~Composition~~ composition according to Claim 14, wherein said lipophilic phase has an HLB value equal to 14 and it represents between 50 and 95% by weight of the composition.

16. (Previously Presented) A composition according to claim 14, wherein the surfactant phase represents between 1% and 30% by weight of the composition.

17. (Previously Presented) A composition according to claim 14, wherein the co-surfactant phase represents between 3% and 32% by weight of the composition.

18. (Previously Presented) A composition according to claim 14, wherein said hydrophobic active principle is a statin.

19. (Previously Presented) A composition according to Claim 18, wherein said statin is simvastatin.

20. (Previously Presented) A composition according to Claim 19, wherein said simvastatin represents between 0.1% and 6% by weight of the composition.

21. (Currently Amended) A composition according to claim 14, wherein said hydrophobic active principle is simvastatin and wherein said simvastatin represents by weight between 0.1% and 6% of the composition, said lipophilic phase represents by weight between 52% and 70% of the composition, said surfactant phase represents by weight between 5% and 30% of the composition, and said co-surfactant phase is comprised of propylene glycol monocaprylate, wherein propylene glycol monocaprylate represents by weight between 15% and 30% of the composition.

22. (Previously Presented) A composition according to Claim 21, wherein said propylene glycol monocaprylate represents by weight between 15% and 25% of the composition.

23. (Previously Presented) A composition according to Claim 21, wherein said propylene glycol monocaprylate represents by weight between 20% and 30% of the composition.

24. (Previously Presented) A composition according to Claim 21, wherein said surfactant and co-surfactant are in a 0.5 ratio by weight.

25. (Previously Presented) A composition according to claim 21, wherein said lipophilic phase has an HLB value of 14.

26. (Previously Presented) A composition according to claim 21, wherein said lipophilic phase is comprising of lauric macrogolglycerides.

27. (Previously Presented) A composition according to claim 21, wherein said surfactant phase has an HLB value between 5 and 20.

28. (Previously Presented) A composition according to claim 21, wherein said surfactant phase is caprylocapric magrogol glyceride.